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Organometallic compounds offer broad scope for the design of
therapeutic agents, but this avenue has yet to be widely explored.
A key concept in the design of anticancer complexes is optimization
of chemical reactivity to allow facile attack on the target site (e.g.,
DNA) yet avoid attack on other sites associated with unwanted
side effects. Here, we consider how this result can be achieved for
monofunctional ‘‘piano-stool’’ ruthenium(II) arene complexes of
the type [(6-arene)Ru(ethylenediamine)(X)]n. A potentially im-
portant activation mechanism for reactions with biomolecules is
hydrolysis. Density functional calculations suggested that aqua-
tion (substitution of X by H2O) occurs by means of a concerted
ligand interchange mechanism. We studied the kinetics and equi-
libria for hydrolysis of 21 complexes, containing, as X, halides and
pseudohalides, pyridine (py) derivatives, and a thiolate, together
with benzene (bz) or a substituted bz as arene, using UV-visible
spectroscopy, HPLC, and electrospray MS. The x-ray structures of
six complexes are reported. In general, complexes that hydrolyze
either rapidly {e.g., X  halide [arene  hexamethylbenzene
(hmb)]} or moderately slowly [e.g., X  azide, dichloropyridine
(arene  hmb)] are active toward A2780 human ovarian cancer
cells, whereas complexes that do not aquate (e.g., X  py) are
inactive. An intriguing exception is the X thiophenolate complex,
which undergoes little hydrolysis and appears to be activated by a
different mechanism. The ability to tune the chemical reactivity of
this class of organometallic ruthenium arene compounds should be
useful in optimizing their design as anticancer agents.
anticancer  bioorganometallic  hydrolysis  kinetics  ruthenium
complexes
Organometallic chemistry has evolved rapidly during the last50 years, notably in areas related to catalysis and materials
(1). Applications in biology andmedicine are in their infancy, but
the potential for exciting developments is clear (2). In the field
of cancer chemotherapy, the cyclopentadienyl complex
[Cp2TiCl2] has been in clinical trials (3, 4), and a ferrocene
derivative of Tamoxifen is a candidate for trials for breast cancer
therapy (5). The successful design of second- and third-
generation platinum anticancer drugs, now widely used in the
clinic, has demonstrated that detailed knowledge of the factors
that control ligand substitution and redox reactions is very
valuable in drug design. The chemical reactivity of the complexes
can be chosen so as to balance the inertness required for the drug
to reach its target site (e.g., DNA) and minimize attack on other
sites (side effects) yet allow activation necessary for binding to
the target. Thus, cis-[PtCl2(NH3)2], cisplatin, is relatively unre-
active in high-chloride media (e.g., blood plasma) and is acti-
vated by hydrolysis near DNA in the nucleus (6). In contrast,
carboplatin and oxaliplatin are relatively inert to hydrolysis, have
a milder spectrum of side effects, and probably attack DNA by
means of chelate ring-opening reactions (7, 8). Exploration of
the factors that control the aqueous chemistry of organometallic
complexes may therefore also allow the design of effective
anticancer agents.
Our studies are focused on monofunctional ruthenium(II) arene
anticancer complexes of the type [(6-arene)Ru(ethylenediamin-
e)(X)]n, where X is a leaving group (e.g., Cl). In these pseudooc-
tahedral ‘‘piano-stool’’ RuII complexes, a -bonded arene (the
‘‘seat’’ of the stool) occupies three coordination sites, and the two
nitrogens of ethylenediamine (en) and X fill the remaining three
sites (the ‘‘legs’’). Although ruthenium has a rich redox chemistry
(9), the presence of an arene greatly stabilizes RuII compared with
RuIII (ref. 10 and references therein). These complexes can exhibit
cytotoxicity toward cancer cells, including cisplatin-resistant cells
(11, 12). In nucleotide adducts, {(6-arene)Ru(en)}2 exhibits a
high selectivity forN7 of guanine and, in contrast to cisplatin, shows
little interaction with adenine (13, 14). Reactions of these chloro
RuII arene complexes with nucleotides appear to involve initial
aquation, and Ru–OH2 bonds appear to be more reactive than
Ru–OH bonds (15), a behavior parallel to that of PtII diam(m)ine
anticancer complexes (16).
Here, we have studied the effect of both X and the arene on the
kinetics and thermodynamics of hydrolysis of [(6-arene)Ru-
(en)(X)]n complexes, with X ranging from halide, pseudohalide,
and pyridine (py) derivatives to thiolate and with the arene ranging
from benzene (bz) to more sterically hindered p-cymene (p-cym)
and hexamethylbenzene (hmb) to multiring [indan (ind) and bi-
phenyl (bip)] complexes. In viewof the high chloride concentrations
in blood plasma and cell culture media, we have also studied
reactions with chloride and with guanine [as guanosine 5 mono-
phosphate (GMP)] as a potential target site on DNA. Density
functional computational methods have been used to elucidate the
mechanism of the aquation reactions, HPLC and electrospray
ionization MS (ESI-MS) have been used to identify the products,
andUV-visible (UV-Vis) spectroscopy has been used to determine
rates and equilibria. The x-ray crystal structures of six complexes are
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reported. Although it is sometimes stated (17) that both RuII and
RuIII oxidation states are ‘‘substitution-inert,’’ we show that the
rates of hydrolysis of these RuII arene complexes can vary over
many orders of magnitude, depending on the nature of X. As for
square-planar PtII complexes, it is possible to design cytotoxic RuII
arene complexes with widely contrasting ligand substitution rates.
Materials and Methods
Materials. The synthesis and characterization of the ruthenium
arene complexes studied here, [(6-arene)Ru(en)X][PF6]n, arene
hmb,XCl (1), Br (5), I (9),N3 (14), and thiophenolate (SPh) (21),
n  1; X  py (16), 3,5-dichloropyridine (dcp) (17), 3,5-
difluoropyridine (dfp) (18), p-cyanopyridine (pcp) (19), and 3-pi-
coline (pic) (20), n 2; arene bip, X Cl (2), Br (6), I (10), and
N3 (15), n 1; arene ind, X Cl (3), Br (7), and I (11); arene
bz, X  Cl (4), Br (8), I (12); arene  p-cym, X  I (13), n  1,
are described in Supporting Text, which is published as supporting
information on the PNAS web site. CF3COOH (TFAH) was
purchased from Acros (Geel, Belgium), and GMP disodium salt
hydrate was purchased from Aldrich.
UV-Vis Spectroscopy. A PerkinElmer Lambda-16 UV-Vis spectro-
photometer was usedwith 1-cmpath-length quartz cuvettes (0.5ml)
and a PTP1 Peltier temperature controller. Spectra were processed
by using UVWINLAB software for Windows 95.
HPLC and ESI-MS. The procedures were similar to those we reported
in ref. 18 and are described in Supporting Text.
X-Ray Crystallography. Details of the structure determinations of
complexes 1, 3, 5, 9, 11, and 19 are provided in Tables 4–7 and Figs.
3–8, which are published as supporting information on the PNAS
web site.
Hydrolysis Equilibria. Normalized areas of HPLC peaks detected by
UV absorption at wavelengths where the absorption of aqua
complexes and their respective parent species presented minimum
differences were used to calculate the hydrolysis equilibrium con-
stants (K) according to Eq. 1:
K C0Aaq2C01  Aaq , [1]
where C0 is the initial concentration of the parent complex, and
Aaq is the normalized area of the HPLC peak for the aqua
complex.
Kinetics.Details of the procedures used to determine rate constants
for substitution of X by H2O, Cl, or GMP by UV-Vis spectroscopy
are given in Supporting Text.
IC50 Values. The concentrations of the complexes that caused 50%
inhibition of the growth of human ovarian A2780 cancer cells were
determined as described in the Supporting Text.
Partition Coefficients and CellDNA Uptake. The octanolwater par-
tition coefficients and uptake of complexes 1 and 21 by A2780
human ovarian cancer cells and the extent of ruthenation of their
DNA were determined as described in Supporting Text.
Computation. Density functional theory calculations were per-
formed by using the AMSTERDAM DENSITY FUNCTIONAL (ADF) (19)
program suite (version 2003.01) (20). Geometries and energies
were obtained by using the nonrelativistic PerdewWang gradient-
corrected functional (PW91) unless otherwise stated. The frozen-
core approximation (21) was applied with the orbitals up to and
including that labeled in brackets as follows: Ru[3d], O[1s], C[1s],
N[1s], Cl[2p], Br[4p], and I[4d]. Basis sets and other details are
described in Supporting Text.
Supporting Information. Details of experimental procedures (syn-
theses; HPLC; ESI-MS; x-ray crystallography; computations; ki-
netics; partition coefficients; cellDNA uptake; crystallographic,
computational, and kinetic data; and separation and identification
of hydrolysis and GMP products) are provided in Tables 4–10 and
Figs. 3–26, which are published as supporting information on the
PNAS web site.
Results
First, we attempted to gain insight into the potential role of the
ligand X in the mechanism of aquation of [(6-arene)Ru(en)X]n
complexes by using computational methods.
Computation. A test of the structural accuracy of the functional
PW91was performed by comparing the fully optimized structure of
[(6-bz)Ru(en)Cl] with the x-ray crystal structure of [(6-p-
cym)Ru(en)Cl][PF6] (12). PW91 overestimated theRu–ligand con-
tacts by 0.03–0.04 Å, except the Ru–Cl distance (2.40 Å), which
was shorter than experiment (2.44 Å). Overall, the agreement with
experimental data was satisfactory.
The reaction modeled was {[(6-bz)Ru(en)X]H2O}3 [TS]3
{[(6-bz)Ru(en)(H2O)]2X}, X Cl, Br, I, and N3 (where TS is
transition state).
The system retained the entering and leaving groups within the
second coordination sphere as appropriate. This substitution pro-
cess can be described in terms of the two parameters Ru–L and
Ru–OH2. In principle, the process could be associative or disso-
ciative, so a preliminary set of calculations was undertaken to map
out the potential energy surface as a function of these two variables.
For X  Cl, the reaction potential energy surface is shown in Fig.
1. An approximate saddle point is located at Ru–O  2.8 Å and
Ru–Cl 3.0 Å, and the corresponding structure was used in a full
transition state optimization leading to a structure with Ru–O 
2.99Å andRu–Cl 3.28Å lying 17 kcalmol1 above the reactants.
The barrier height does not vary dramatically with different
functionals (Table 8), nor does it change when the arene ligand is
changed from simple bz to hmb. Having established that PW91
Fig. 1. Reaction potential energy surface for the hydrolysis of [(6-bz)Ru(en)Cl].
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basis I with bz as the arene ligand is a suitablemodel system,we then
explored the effect of varying X, assuming that the same inter-
change mechanism applies. The results show that the reaction
barriers and overall reaction energies for the aquation of the halide
(Cl, Br, and I) and pseudohalide N3 in {(6-bz)Ru(en)}2 com-
plexes follow the order Br  Cl  I  N3 (Table 1).
Next, the anionic X ligand was replaced by a neutral py donor,
either py itself or pcp, dcp, dfp, or pic. A similar concerted
mechanismwas used with entering and leaving groups remaining in
the second coordination sphere. The calculated order of hydrolysis
rates based on the forward reaction barrier heights is pcp		 dcp	
dfp pic	 py, although it should be noted that the barriers for the
last four ligands span only 2 kcalmol1 (Table 1).
These data suggested that the nature of X could control the
hydrolysis of these complexes, and this hypothesis was confirmed by
the following experiments.
Synthesis and Characterization of Complexes.The syntheses followed
previously described routes (12, 22–24). The x-ray crystal structures
of complexes 2, 13, 22, and 23 have already been reported (12, 13);
those of the halo complexes [(6-hmb)Ru(en)X][PF6], X Cl (1),
Br (5), I (9), [(6-ind)Ru(en)X][PF6] (XCl (3), and I (11), as well
as the pcp complex [(6-hmb)Ru(en)(pcp)][PF6]2 (19), are reported
here (details are provided in Supporting Text). All adopt the familiar
piano-stool structure (Figs. 3–8).
Hydrolysis Products. Aqueous solutions of [(6-hmb)Ru(en)
X][PF6]n [X  Cl (1), Br (5), I (9), N3 (14), dcp (17), dfp (18), pcp
(19), and pic (20)] were allowed to equilibrate for 24–48 h at
ambient temperature and were then analyzed by HPLC. Two well
separated peaks were observed for each complex corresponding to
the aqua adduct and the respective parent cation (Fig. 9), as
identified by the subsequent ESI-MS assays (Figs. 10 and 11). As an
example, for complex 9 [(6-hmb)Ru(en)I][PF6], the fraction elut-
ing at 3.76 min gave rise to two ion peaks at mz 323.0 and 437.1,
assignable on the basis of mass-to-charge ratios and isotopicmodels
(18) (Fig. 10) to the aqua complex [(6-hmb)Ru(en)(H2O)]2
(calculatedmz of 323.1 for [(6-hmb)Ru(en)(H2O)]2–H2O–H)
and its trifluoroacetato (TFA) adduct (calculated mz of 437.1 for
[(6-hmb)Ru(en)(TFA)]), respectively. The fraction eluting at
11.32 min gave a peak at mz  450.8 corresponding to the intact
cation of 9 (calculatedmz of 451.0 for 9). Analogous products in
aqueous equilibrium solutions of complexes 1, 3, 12, 13, 14, 15, 17,
18, 19, and 20 were also identified by ESI-MS analysis of their
HPLC fractions (Figs. 11–15).
Hydrolysis Kinetics.Dissolution of compounds 1–21 in 19:1 mixtures
of water and methanol at 298 K gave rise to hydrolysis as indicated
by the concomitant changes in UV-Vis absorption bands. A typical
time evolution for [(6-ind)Ru(en)I][PF6] (11) at 298 K is shown in
Fig. 16. The first-order exponential decay of the absorbance of 11
at 270 nm gave a hydrolysis rate constant kH2O of 5.58 
 104 s1.
The hydrolysis rate constants and half-lives for compounds 1–21 are
shown in Fig. 2 and listed in Tables 2, 9, and 10.
The hydrolysis rates vary over several orders of magnitude.
Within each group of complexes containing the same coordinated
arene, the hydrolysis rate decreases in the order Cl  Br 	 I.
Replacement of chloride (in complex 1 or 2) by the pseudohalide
N3 (to give complexes 14 and 15) has an even greater effect on the
hydrolysis rate (Fig. 2 and Table 2), slowing it down by 40-fold.
Changing the leaving group to py, pic, or SPh, as in 16, 20, and 21,
slows down hydrolysis dramatically, such that it was too slow to
observe. The introduction of a substituted py, however, such as dcp
in 17 and dfp in 18, led to observable hydrolysis, albeit slower than
the corresponding Cl complex by a factor of1,400. The hydrolysis
rate of the pcp complex 19was similar to that of the N3 complex 14.
For complexes containing the same leaving group Cl, the hydro-
lysis rate decreased with variation of the coordinated arene in the
order hmb 	 tetrahydroanthracene (tha)  dihydroanthracene
(dha) (18)  ind 	 bz 	 bip, and for I complexes the order was
hmb 	 p-cym 	 ind 	 bip  bz (Tables 2 and 9).
Hydrolysis Equilibria. TheCl and Br complexes hydrolyzed to	75%
at equilibrium, but the I complexes (9, 12, and 13) were 50%
hydrolyzed, the least being for the p-cym complex 13 (5%). Simi-
larly, the azide compounds hydrolyzed only to a very small extent,
5% for complexes 14 and 15 (Fig. 2 and Table 2).
Although the dcp, dfp, and pcp complexes 17, 18, and 19
hydrolyze only slowly, the extent of their hydrolysis at equilibrium
is significant (32–60%).However, no significant aquation (1%) of
the py and pic complexes 16 and 20 was detected by HPLC.
Substitution of I, N3, dcp, py, and SPh by Cl. The possibility that some
complexes might be transformed into their chloro analogs in
high-chloride (biological) media was investigated. At 310 K, signif-
icant changes in theUV-Vis absorption of complexes 13 (p-cymI),
15 (bipN3), 17 (hmbdcp), and 21 (hmbSPh) were observed in
104mMNaCl solution (Figs. 17, 18, 20, and 24). HPLC separations
(Figs. 17, 18, 20, and 25) indicated that the majority of the I leaving
group in 13 was substituted by Cl, but N3 in 15 and dcp in 17 were
only partially substituted after 24 h and for SPh 3%.The variation
of absorption with time gave rise to the reaction half-lives listed in
Table 3. Both UV-Vis spectra and HPLC assays (Fig. 19) showed
that no substitution of the py ligand in 16 byCl occurredwithin 24 h.
Partition Coefficients and CellDNA Uptake. The octanolwater
partition coefficients (log Poct) of 1 and 21 were determined to
Table 1. Selected bond lengths, forward reaction barriers, and overall reaction energies from
density functional theory calculations for reactions {[(6-bz)Ru(en)X]nH2O} 3 [TS] 3
{[(6-bz)Ru(en)(H2O)]2X}
X
Ru-XRu-OH2
reactant, A˚
Ru-XRu-OH2
TS, A˚
Ru-XRu-OH2
product, A˚
E‡,
kcalmol1
Ereac,
kcalmol1*
Cl 2.473.94 3.282.99 4.102.20 17.0 2.5
Br 2.633.99 3.392.88 4.242.21 16.0 1.9
I 2.854.44 3.662.95 4.482.22 18.1 5.2
N3 2.154.34 2.773.00 3.752.19 25.4 8.2
pcp 2.113.89 2.952.75 3.922.18 8.4 6.7
dcp 2.134.04 2.902.67 3.922.17 21.6 5.2
dfp 2.124.08 2.892.71 4.002.18 22.6 5.4
py 2.123.85 2.912.77 3.882.17 23.5 5.1
pic 2.123.73 2.842.72 3.882.17 22.6 3.9
TS, transition state.
*Ereac values relative to reactant species at zero.
Wang et al. PNAS  December 20, 2005  vol. 102  no. 51  18271
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be 1.53  0.02 and 0.17  0.02, respectively. Treatment of
A2780 human ovarian cancer cells with 20 M 1 or 21 for 24 h
gave rise to cellDNA-bound [Ru] levels of 74 37.1 4.0 and
136  54.2  2.7 pmol per 106 cells, respectively.
Reactions of N3, py, dcp, and SPh Complexes with GMP. The possi-
bility that slowly aquating complexes could react directly with
guanine was investigated. Reactions of 0.5 mM 15, 16, 17, or 21
with 0.5 mMGMPwere followed by UV-Vis spectrometry at 298
K. The py complex 16 did not react (Fig. 22). Reaction half-lives
were determined from absorbance-versus-time plots for 15, 17,
and 21 and, for comparison, for 1 and 13, which undergo fast
aquation (Figs. 21, 23, 24, and 26 and Table 3).
Positive-ion mass spectra of HPLC fractions (Figs. 21–23 and
25) indicated that the second fractions for reactions of 15 and 17
(identical to that for 21) with GMP contain GMP adducts, giving
rise to singly charged ion peaks at mz  678.2 (calculated mz
of 678.1 for [(6-bip)Ru(en)(GMP)]  H) and 686.3 (calcu-
lated mz of 686.2 for [(6-hmb)Ru(en)(GMP)]  H), respec-
tively. No GMP adduct of 16 was detectable (Fig. 22). Hence, it
appears that N3, dcp, and SPh can all be substituted by GMP.
Cytotoxicity. The concentrations of complexes that achieved 50%
inhibition of the growth of human ovarian A2780 cancer cells (IC50
values) were determined (Fig. 2 and Table 2). The activity of most
of the complexes against this cancer cell line is at least comparable
to that of carboplatin (IC50 6 M), and several approach that of
cisplatin (IC50 0.6M). Exceptions are the hmbpy and hmbpic
complexes 16 and 20 (for which no significant hydrolysis was
observed); the former is inactive, and the latter is weakly active. For
complexes containing the same leaving group, the cytotoxicity
increases with the size of the coordinated arene in the order bz 
p-cym (11)  hmb  bip  dha  tha.
It is notable that the Cl and N3 complexes containing either hmb
or bip as arene ligands all exhibit good activity (IC50 values of 4–18
M) despite the significant difference in their rates and extent of
hydrolysis. Also, the thiolate complex 21 exhibits significant activity
despite being relatively inert to hydrolysis.
Discussion
Mechanism of Hydrolysis. The density functional theory calculations
(Fig. 1) suggested that aquation of [(6-bz)Ru(en)X]n complexes
proceeds via a concerted interchange pathway rather than a step-
wise dissociationcoordination process. The reaction does not
appear to be strongly associatively nor dissociatively activated,
because the Ru–Cl bond at the transition state extends by 0.81 Å
relative to the reactant species, whereas the Ru–O bond is 0.79 Å
longer than in the aqua product (Table 1).
In an interchange associative pathway (Ia), bond-breaking
alone is not rate controlling, and a heavier halide makes
crowding of the central Ru atom unfavorable in associative states
Fig. 2. Correlation of hydrolysis with cytotoxicity. (Upper) Structures of
complexes, arenes, and leaving groups. (Lower) Hydrolysis rates, equilibrium
percentage of total Ru as [(6-hmb)Ru(en)(H2O)]2 ([Ru(H2O)]e %), and A2780
human ovarian cancer cell IC50 values for [(6-hmb)Ru(en)X]n complexes with
various leaving groups (X). Data for other arene complexes are listed in
Table 2.
Table 2. Hydrolysis data for [(6-arene)Ru(en)X][PF6]n (n  1 or
2) complexes at 298 K and cytotoxicity (IC50) toward A2780
human ovarian cancer cells
Complex Arene X kH2O, 103 s1 [Ru(H2O)]e, % IC50, M
18 hmb dfp 0.0208  0.0001 32.6 ND
2 bip Cl 1.24  0.13 76.2 5†
6 bip Br 1.05  0.04 ND ND
10 bip I 0.321  0.045 ND 5
15 bip N3 0.0315  0.0043 4.5 4
3 ind Cl 2.29  0.14 76.3 8
7 ind Br 2.16  0.05 ND ND
11 ind I 0.512  0.046 ND ND
4 bz Cl 1.98  0.02 98.1 17†
8 bz Br 1.50  0.02 ND ND
12 bz I 0.294  0.003 20.5 20†
13 p-cym I 0.948  0.008 5.0 9†
22 dha Cl 2.23  0.02 80.4* 2†
23 tha Cl 2.36  0.02 80.0* 0.5†
Data for other hmb complexes are provided in Fig. 2. [Ru(H2O)]e, equilib-
rium percentage (average of three independent measurements) of aqua
complex in 2 mM solution of Cl complex; ND, not determined.
*In 15 mM NaClO4 (18).
†Data are from ref. 11.
Table 3. Half-lives for substitution reactions of leaving groups in
[(6-arene)Ru(en)X]n by H2O, Cl, and GMP at 298 K
Complex (arene) X
t12, min
H2O Cl GMP
1 (hmb) Cl 0.44 24.7
13 (p-cym) I 12.2 2.73 22.6
15 (bip) N3 367 1122 554
16 (hmb) py — — —
17 (hmb) dcp 537 631 578
21 (hmb) SPh — 107 631
—, no reaction.
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with a higher coordination number (seven) (25, 26). The effect
of halides on the hydrolysis rate of RuII arene complexes is
opposite to that reported for platinum compounds
[PtXn(H2O)4n](2n), for which Br analogs of Cl complexes
hydrolyze faster in all three hydrolysis steps (27).
The effective electronegativity of N3 lies between that of Cl and
Br (28); however, the hydrolysis rates of N3 complexes 14 and 15 are
much lower than those of theCl andBr analogs. This lower ratemay
be due to the increased steric bulk of this polyatomic pseudohalide;
an Ia substitution pathway is more influenced by steric factors than
an Id (dissociative) pathway (18).
For arene enRuII halide complexes, the hydrolysis rates decrease
with increase in the electron-accepting ability (29) of the arene
(hmb p-cym thadha indan bip bz), with the exception
that aquation of bz complexes is slightly faster than for the bip
analogs, perhaps due to steric hindrance from the pendant phenyl
ring being twisted toward X (12, 18). We used 19:1 H2O:MeOH
unbuffered solutions for hydrolysis (as well as Cl and GMP) studies
because the aqua adducts have high pKa values (8.0) and hydro-
lysis reduces the pH only slightly [from 7 to 6.2 for 2, 22, and 23
(18)]. The calculated reaction barriers and overall reaction energies
for the aquation of the halide and azide {(6-bz)Ru(en)}2 com-
plexes follow the order Br  Cl  I  N3 (Table 1), in agreement
with the experimental hydrolysis rates, Cl  Br  I  N3 (Fig. 1),
confirming that the higher activation energies are responsible for
the slower hydrolysis of the I and N3 complexes. The larger leaving
groups py, pic, and SPh in 16, 20, and 21 make the Ru center less
accessible to an incoming ligand. However, electron-accepting
substituents on the py ring such as Cl, F, or CN, as in 17, 18, and
19, weaken the donor ability of the py nitrogen, as seen by themuch
lower pKa values of dfp, dcp, and pcp (2) compared with pic and
py (5–6) (30) and lead to an increase in the hydrolysis rate.
Given the different charge states, direct comparisons of calcu-
lated activation energies for negative (Cl, Br, I, and N3) and neutral
(py and py derivatives) X ligands (Table 1) are problematic. For
example, the hydrolysis rate of the hmbCl complex 1 is100-fold
faster than that of the hmbpcp complex 19, but the forward
reaction barrier for 19 is only half that of 1. However, among the
py and py-derivative complexes, the calculated order of hydrolysis
rates based on the forward reaction barrier heights (pcp		 dcp	
dfp  pic 	 py) is in agreement with the experimental data: The
hydrolysis rate of the hmbpcp complex (19) is 12 times faster
than that of the hmbdcp and hmbdfp compounds 17 and 18, and
no hydrolysis was observed for the hmbpy complex 16, although
the difference between the barriers for the four complexes is only
2 kcalmol1. An exception is that no hydrolysis was observed for
the hmbpic compound 20 by UV-Vis spectroscopy, although the
calculated reaction barrier is the same as that for 18 (half-life of 555
min). However, the very small equilibrium constant (Table 10) and
very small change in the UV-Vis absorption made the rate difficult
to determine.
Within this family of (arene)RuII complexes, therefore, the
hydrolysis rates are tunable, which is potentially useful in the design
of anticancer complexes. Hydrolysis is known to be an important
mechanism of activation for the anticancer drug cisplatin (6), which
has hydrolysis rate constants of 7.56
 105 and 6.32
 105 s1 for
the first and second chloride ligands, respectively (31), significantly
lower than the rate constants of Ru–Cl hydrolysis in these arene
complexes. However, replacing Cl by pyridyl ligands can readily
effect a 40- to 1,400-fold deceleration. In the case of compounds 17,
18, and 19, these alterations result in compounds with hydrolysis
rates comparable to cisplatin. A variety of other py derivatives could
be used for fine-tuning.
In {(6-arene)RuII(en)}2 complexes, the chelated en and arene
ligands also influence hydrolysis rates. Our previous work (18) has
shown that en cis to the leaving group (Cl) slows down aquation of
RuII arene (bip, dha, and tha) complexes, just as 2,2-bipyridine
(bpy) slows down substitution of the aqua ligand in [(6-
C6H6)Ru(bpy)(H2O)]2 (32). Replacement of en by acetylaceto-
nate to give {(6-arene)RuII(acac)} complexes accelerates hydro-
lysis (33), supporting the above arguments.
Arene ligands such as bz are reported to exhibit a strong
translabilizing effect for the aqua ligand in [(6-C6H6)Ru(H2O)3]2
(34). Also, this class of strong -acid ligands is able to accept
electron density from the central RuII giving rise to a higher charge
on the metal, so that RuII in {(6-arene)RuII}2 behaves more like
a RuIII center (18, 35). Acidic hydrolysis of RuIII complexes such as
[Ru(NH3)4X2] and [Ru(NH3)5X]2 (XCl, Br, and I) occurs via
an SN2 associative pathway (36) in which bond-making is more
important than bond-breaking. Therefore, the electron-accepting
effect of strong -acid arene ligands might be responsible for the
shift toward a more associative pathway in the Id7 Ia mechanistic
continuum for the {(6-arene)RuII(en)}2 complexes studied here
(36, 37).
Activation Pathways and Cytotoxicity.Our previous work has shown
that the interaction of [(6-bip)Ru(en)Cl] (2) with amino acids
(38, 39), peptides (40), proteins (39), and DNA bases (15) involves
aquation as the first step. The chloro complexes are relatively inert.
Such behavior appears to parallel that of the chloro PtII anticancer
complex cisplatin, the activation of which involves intracellular
aquation (6, 16, 41). The aqua ligands are much more reactive, for
example, toward substitution by guanine bases on DNA (42).
In general, for the arene complexes studied here, those that
hydrolyze exhibit high cytotoxicity, and those that do not hydrolyze
are inactive or weakly active. For optimizing drug design and
reducing side effects, it is sometimes beneficial to decrease chemical
reactivity but retain cytotoxicity. Therefore, our discovery of com-
plexes that hydrolyze at only moderate rates (e.g., hmbN3 and
hmbdcp) or extremely slowly (hmbSPh) yet exhibit significant
activity may provide valuable leads for drug optimization.
The concentration of chloride in bloodplasmaor culturemedium
is104 mM, and the cytoplasmic [Cl] is22 mM (43). Therefore,
substitution of nonchloride leaving groups such as I, Br, and N3 by
Cl in these media could be involved in the mechanism of action. In
104 mMNaCl solution, the substitution of the I leaving group in 13
was complete within minutes at 298 K, with a half-life (2.7 min)
much shorter than that of the hydrolysis (12.2 min), implying that
I in 13 will be substituted by Cl instead of H2O when this complex
is dissolved in 104 mM NaCl solution. In contrast, under the same
conditions, the half-lives for substitution of N3 in 15 (1,120min) and
dcp in 17 (631 min) by Cl are longer than those for hydrolysis of the
respective complexes (367 and 537 min, respectively), indicating
that the substitution of N3 and dcp by Cl involves aquation as the
first step in the reaction.
About twice as much Ru from the SPh complex 21 was taken up
by A2780 cells as from the chloro complex 1, in line with its (23
times) higher octanolwater partition coefficient. However, the
level of ruthenation of cellular DNA was 2 times higher for 1,
consistent with its 2.5-times higher cytotoxicity (Fig. 2 and Table 9).
This finding suggests that DNAmay be an important target site for
RuII arene complexes, in agreement with our previous work, which
showed specific binding to G bases (12, 40, 44). Therefore, in this
work, we used GMP as a model to study activation pathways. For
the bipN3 (15) and hmbdcp (17) complexes, GMP binding (t1/2
554 and 578 min, respectively) is faster than substitution of N3 and
dcp by Cl (1,122 and 631 min) but slower than hydrolysis (367 and
537 min). Because the half-lives for reactions of the aqua adducts
of bipCl (2) and hmbCl (1) with GMP are 108 (15) and 24.3
(24.7–0.44; Table 3) min, respectively, these data strongly suggest
that the reactions of 15 and 17 with DNA (GMP) will involve
aquation of the parent complexes as the first (rate-controlling) step.
In contrast, the py complex 16 does not hydrolyze or react with Cl
or GMP and is inactive toward A2780 cells.
Interestingly, the active SPh complex 21 does not undergo
aquation, and substitution of SPh by Cl occurs at a rate much faster
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than the GMP binding (Table 3) but to a very low extent (3%
under [Cl]  104 mM). Therefore, 21 may react directly with
guanine, especially in the cell nucleus where [Cl] is low (4 mM; ref.
45). This reaction pathway is analogous to that of the second-
generation platinum drug carboplatin, which is stable in water and
reacts with chloride only very slowly and directly with nucleophiles.
It seems likely that 21 is activated by means of oxidation of the
bound SPh to the sulfenate or sulfinate by oxygen, analogous to our
recent finding for glutathione complexes (40). Glutathione sulfe-
nate is readily displaced from Ru by N7 of guanine.
Conclusions
We have shown that ligand substitution reactions of organome-
tallic RuII arene complexes can be finely controlled, not only by
the choice of the arene but also by the other ligands, in particular
by a chelated ethylenediamine and a monofunctional leaving
group (X). The hydrolysis rates of [(6-arene)Ru(en)(X)]n
complexes vary over many orders of magnitude, from half-lives
of seconds (hmbCl) to minutes (e.g., hmbN3) to hours (hmb
dfp, dcp; bipN3) or half-lives that are too slow to be measured
(hmbpy, SPh) at 298 K. Density functional theory calculations
suggest that aquation occurs via a more associative pathway in
a Ia 7 Id mechanistic continuum for which bond-making is of
greater importance than bond-breaking. For bz complexes, the
calculated reaction barriers and overall reaction energies follow
the order Cl  Br  I  N3, in agreement with experimental
data. Hydrolysis provides a pathway for activation. In general,
complexes that are readily hydrolyzed are cytotoxic (e.g., hmb
halide), and those that do not hydrolyze (e.g., hmbpy or pic) are
inactive or weakly active.
The Br and I complexes may be prodrugs for the Cl complex in
view of the high concentration of Cl in extracellular biological
media (104 mM), but py in the biologically inactive hmb complex
16 cannot readily be substituted by Cl, and the half-lives for
substitution ofN3 and dcp byCl are longer than those for hydrolysis.
For the latter complexes, the hydrolysis activation pathway pre-
dominates, as it does for the Cl complexes.
An unexpected exception is the moderately active hmbSPh
complex 21, which undergoes little hydrolysis or reaction withCl yet
reacts withGMP at a similar rate to the hmbdcp complex. It seems
likely that the thiolate ligand in 21 is oxidized to sulfenate or
sulfinate, which provides a facile route for displacement by guanine
(DNA; ref. 40).
These findings provide a potential strategy for optimizing the
anticancer activity of half-sandwich Ru(II) arene complexes whilst
minimizing side effects by tuning substitution reactions, a strategy
that has previously been successful for Pt anticancer drugs. Wider
exploration of the kinetics and thermodynamics of metal–ligand
substitution reactions should aid the tuning of the biological activity
of many other families of metal complexes and of organometallic
complexes in particular.
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